Drug Profile
Research programme: alpha-particle radiotherapies - Algeta
Alternative Names: Alpha-particle emitters - Algeta; ATI-OC-1; ATI-OC-2; OC-3Latest Information Update: 11 Mar 2014
Price :
$50
*
At a glance
- Originator Algeta
- Class Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Ovarian cancer
Most Recent Events
- 06 Mar 2014 Algeta has been acquired by Bayer
- 24 Feb 2009 Suspended - Preclinical for Ovarian cancer in Norway (Intraperitoneal)
- 29 Nov 2006 Preclinical development is ongoing with OC-3 for ovarian cancer